Jakson kuvaus
Up to 95% of pancreatic cancer patients have a KRAS mutation in their tumor. For decades, it was considered impossible to target with a drug. What changed?
To get the latest information, host Alisyn Camerota is joined by Dr. Eileen O'Reilly, medical oncologist and Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center, to unpack what RAS and KRAS actually are, why this gene resisted treatment for so long, and what the recent approval of Rasonque™ (daraxonrasib) means for patients with metastatic pancreatic cancer.
Dr. O'Reilly explains the biology…
Sivusto: share.transistor.fm

